Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 5/20 | 0.39 |
| ▸ | MMP9 | P14780 | 3/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 7/20 | 0.38 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | ANPEP | P15144 | 1/20 | 0.34 |
| ▸ | BCL2 | P10415 | 3/20 | 0.34 |
| ▸ | BCL2L1 | Q07817 | 3/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12864435 | 0.93 | MCL1 (0.39) | MMP2MMP9MCL1CACNA1BP2RX7 | |
| SCHEMBL10082718 | 0.91 | MMP2 (0.40) | MMP2MMP9MCL1CACNA1BP2RX7 | |
| SCHEMBL15483922 | 0.86 | ELANE (0.42) | MMP2MCL1 | |
| SCHEMBL15258574 | 0.86 | ELANE (0.42) | MMP2MCL1 | |
| SCHEMBL3372052 | 0.86 | ELANE (0.42) | MMP2MCL1 | |
| SCHEMBL10221213 | 0.86 | ELANE (0.42) | MMP2MCL1 | |
| SCHEMBL3050430 | 0.85 | HDAC8 (0.39) | MMP2MMP9MCL1 | |
| SCHEMBL4449192 | 0.85 | HDAC8 (0.39) | MMP2MMP9MCL1 | |
| SCHEMBL3050428 | 0.85 | HDAC8 (0.39) | MMP2MMP9MCL1 | |
| SCHEMBL3372755 | 0.82 | AAK1 (0.46) | MMP2MMP9MCL1CACNA1BP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8674088-B2 | Antiviral phosphinate compounds | GILEAD SCIENCES, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-7893264-B2 | viricides comprising phosphinic acid compounds and/or mixed with carriers, nucleoside analogues, interferons or pegylated interferons; treating hepatitis C or a hepatitis C associated disorders in animals; side effect reduction | GILEAD SCIENCES, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20080057031-A1 | Antiviral phosphinate compounds | GILEAD SCIENCES, INC. (US) | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080057031-A1 | Antiviral phosphinate compounds | PHOSPHO1, MAVS, ITPA | MMP2 4385/4885MMP9 4292/4885MCL1 1279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.